Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bicycle Therapeutics (BCYC) Current Deferred Revenue (2018 - 2026)

Bicycle Therapeutics (BCYC) has disclosed Current Deferred Revenue for 9 consecutive years, with $2.8 million as the latest value for Q1 2026.

  • For Q1 2026, Current Deferred Revenue fell 77.68% year-over-year to $2.8 million; the TTM value through Mar 2026 reached $2.8 million, down 77.68%, while the annual FY2025 figure was $3.0 million, 97.09% down from the prior year.
  • Current Deferred Revenue hit $2.8 million in Q1 2026 for Bicycle Therapeutics, down from $3.0 million in the prior quarter.
  • Across five years, Current Deferred Revenue topped out at $135.2 million in Q4 2023 and bottomed at $1.2 million in Q2 2022.
  • Average Current Deferred Revenue over 5 years is $26.0 million, with a median of $12.5 million recorded in 2025.
  • Year-over-year, Current Deferred Revenue surged 1726.95% in 2023 and then tumbled 97.09% in 2025.
  • Bicycle Therapeutics' Current Deferred Revenue stood at $7.4 million in 2022, then soared by 1726.95% to $135.2 million in 2023, then dropped by 24.81% to $101.7 million in 2024, then crashed by 97.09% to $3.0 million in 2025, then fell by 5.61% to $2.8 million in 2026.
  • According to Business Quant data, Current Deferred Revenue over the past three periods came in at $2.8 million, $3.0 million, and $12.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.